ClinicalTrials.gov
public full text
Public Domain
Axumin PETMRI Imaging Following Focal Cryo-ablation (FCA)
This is a prospective outcomes study assessing quality of life and oncological control at pre-defined time points following FOCAL CRYO-ABLATION (FCA). The investigator's standard of care is to perform an Magentic Resonance Imaging (MRI) and prostate biopsy two years following FCA. The prostate biopsy assesses both the presence of in field and out of field disease. The role of Axumin PET/MRI for detecting disease following FCA has not been previously examined.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Decade-Long Insights Into Transperineal Prostate Biopsy in a West China Population#865270
- PET Scan in Treating Patients With Metastatic Prostate Cancer#1112375
- Comparison of Intermittent Androgen Deprivation Therapy With or Without Irradiation Recovery in Prostate Cancer Patients#1030474
- 18F-DCFPyL Positron Emission Tomography (PET) in Intermediate or High Risk Prostate Cancer#903235
- 18F-FAPI-04 PET/CT and PET/MR in Patients With Various Types of Malignant Tumors#1031789
Record · ID 900278
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive